Last reviewed · How we verify
NCT04282694: PSP
PRogetto Salute Parma
trial testing Low-dose computed tomography (LDCT) in Smoking in 9 participants. Terminated before completion.
30 October 2020
Quick facts
| Lead sponsor | University of Parma |
|---|---|
| Status | Terminated |
| Study type | OBSERVATIONAL |
| Enrollment | 9 |
| Start date | 12 February 2020 |
| Primary completion | 30 October 2020 |
| Estimated completion | 30 October 2020 |
| Sites | 1 location across Italy |
Drugs / interventions tested
- Low-dose computed tomography (LDCT)
Conditions studied
- Smoking — all drugs for Smoking →
- Smoking Habit — all drugs for Smoking Habit →
- Smoking, Tobacco — all drugs for Smoking, Tobacco →
- Smoking, Cigarette — all drugs for Smoking, Cigarette →
Sponsor
University of Parma
Who can join
Adults 50 to 74, any sex, with Smoking or Smoking Habit. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This project from the University Hospital of Parma (AOUPR) aims to verify the feasibility of a prevention program in our district, relying on advanced technological resources and highly experienced team in lung cancer early diagnosis, in order to identify useful elements towards the applicability of such a prevention program on a large scale (regional, national). Uncontrolled, monocentric experimental study with dynamic enrollment and prospective data collection, aimed at implementing a prevention program based on scientific evidence. This study is set to verify the applicability and feasibility of a lung cancer prevention program in a real context, including a preliminary evaluation at the smoking cessation clinic and a LDCT assessment with subsequent LDCT follow-up for participants who show indeterminate findings at the first LDCT (LDCT baseline) exam. The main objective of the study is to verify the feasibility of a lung cancer prevention program according to internationally validated scientific methods. Secondary objectives: 1. To evaluate the use of local smoking cessation clinics and their effects in terms of smoking cessation (primary prevention) 2. To evaluate the outcomes of the program in terms of number of patients with early (presymptomatic) lung cancer treated with minimally invasive surgery (secondary prevention) 3. To evaluate the number of false positives and their diagnostic work-up (PET-CT, CT-guided biopsy, bronchoscopy) Primary endpoint: \- Percentage of enrolled subjects to whom the program was offered within 60 days from the date of enrolment and percentage of those who stop smoking for at least 12 months Secondary endpoints: * To describe the organizational model, human resources employed, difficulties encountered and elements that have favoured its realization * To measure the variation in smoking habits in enrolled smokers * To describe the effect of annual LDCT on lung cancer diagnosis rates, considering size, shape, histology and site * To measure the consequent demand for further diagnostic investigations and treatment * To measure the number of false positives Subjects at high risk of lung cancer screened by the medical team of the AOUPR or by GPs to join the prevention program. Inclusion criteria * Age between 50 and 75 years * Equivalent tobacco intoxication of ≥ 15 cigarettes per day for ≥25 years or ≥ 10 cigarettes per day for ≥30 years * Status of current smoker or ex-smoker for \<10 years. Exclusion criteria • Personal history of cancer within the prior 5 years We expect to recruit around 500 people in 1 year. This sample size is considered adequate based on the available resources, both human and economic. After closing and adjusting the database and before data analysis, a document called Statistical Analysis Plan (SAP) will be drawn up. It will consist of the following paragraphs: * Statistical methods planned in the study protocol; * Size of the sample; * Management of missing data; * Evaluation of the endpoints; * Statistical models that will be applied in the analysis. The socio-demographic characteristics of the enrolled subjects, the adopted organizational methods and the effects of the prevention program (endpoints) will be analyzed and described using tables and figures. The project "PRogetto Salute Parma: Primary and secondary prevention of smoking-related lung cancer" will be started once approved by the institutional Ethics Committee and authorized by the General Manager. The study is expected to be carried out over 2 years (from the inclusion of the first subject), with an expected period of 1 year for the enrolment and 1 further year for follow-up.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04282694
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Low-dose computed tomography (LDCT)
Trials testing the same drug.
- NCT07478757 — Assessing the Effectiveness of Low-Dose Computed Tomography in Lung Cancer Screening for High-Risk Smokers: A Randomized · NA · not yet recruiting
Other recruiting trials for Smoking
Currently open trials in the same condition.
- NCT07488741 — Comparison of the Effects of Different Chest Techniques on University Students With Smoking Addiction · NA · recruiting
- NCT07443631 — Assessment of HPHC Exposure in Smokers Switching to THS/TP18 With Different Device Variants · NA · recruiting
- NCT07132814 — Abuse Liability for Five Modern Oral Nicotine Products · NA · recruiting
- NCT06966258 — Inspire HER: Inspiring the Heart and Emotions for Radical Health · NA · recruiting
- NCT06713603 — Technology Assisted Motivational Interviewing · NA · recruiting
Other University of Parma trials
Trials by the same sponsor.
- NCT07242079 — Effect Of Pulmonary Rehabilitation in Patients With Alpha-1 Antitrypsin Deficiency · completed
- NCT06977802 — Design and Implementation of a Mobile App for Promoting Healthy and Sustainable Eating Among Students at the University · NA · completed
- NCT06347094 — Precision Nutrition to Improve Cardiometabolic Health With Dietary (Poly)Phenols · NA · recruiting
- NCT06028659 — Investigation of in Vivo Endogenous and/or Exogenous Production of Phenolic Metabolites Using (un)Targeted Metabolomics · NA · recruiting
- NCT06455956 — Use of miRNAs in Growth Hormone Deficiency (GHD) · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04282694 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Parma
- Last refreshed: 19 November 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04282694.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing